Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. will acquire approximately 54.01% of CliniQuantum Ltd. through a definitive share purchase agreement, enhancing its portfolio in the pharmaceutical and quantum technology sectors [1][3]. Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [7]. - NeuroThera Labs Inc. is dedicated to developing novel therapeutics for central nervous system disorders and other underserved health conditions [8]. Transaction Details - NeuroThera will acquire 56,375 CliniQ Shares, representing approximately 54.01% of CliniQ's issued and outstanding ordinary shares, from the Selling Shareholders [3]. - The consideration for the Purchased Shares includes 56,600,000 common shares of NeuroThera, valued at approximately $9,459,954.20 based on the average trading price over the preceding 20 days [4]. - Selling Shareholders may receive earn-out payments of up to $2,500,000, contingent upon achieving specific milestones, including payments for patent applications and a percentage of fundraising proceeds [5]. Closing Timeline - The closing of the transaction is expected within 30 days after submitting an application for an Israeli tax ruling, anticipated around March 31, 2026, subject to closing conditions [6].

Core Insights - The article discusses four stocks that exemplify the GARP (Growth at a Reasonable Price) investment strategy, highlighting their attractive PEG ratios and strong growth outlooks. Group 1: GARP Investment Strategy - GARP investing combines growth and value investing principles, aiming for stocks that are undervalued yet have solid growth potential [4][6]. - The PEG ratio, which is the price-to-earnings ratio divided by the earnings growth rate, is a key metric for GARP investors, with a lower PEG ratio (preferably less than 1) indicating better investment potential [6][7]. Group 2: Stock Analysis - **Nexa Resources**: A global zinc miner with a Zacks Rank of 2 and a Value Score of A, it has a long-term expected growth rate of 35.6% and a discounted PEG and P/E ratio [11]. - **Harmony Biosciences**: A U.S.-based pharmaceutical company with a Zacks Rank of 1 and a Value Score of A, it has a five-year expected growth rate of 27.1% [12]. - **Commercial Metals**: This company, which manufactures and recycles steel and metal products, has a Zacks Rank of 2 and a Value Score of A, with a long-term expected growth rate of 25.5% [14]. - **Suzano**: A manufacturer of pulp and paper products with a Zacks Rank of 1 and a Value Score of A, it boasts a solid long-term expected growth rate of 44.1% [16].

Core Insights - Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5 million to EarthVision Bio, with the transaction expected to close on December 31, 2025 [2][3] Company Overview - EarthVision Bio is developing sustainable products created by Dr. Gordon Moore, founder of Intel, and Dr. Hans Franke, former chairman of Chevron Europe, focusing on eco-friendly alternatives to plastic, molded fiber, wood, and paper products [3] - Nutriband Inc. will retain 10% of the shareholding in EarthVision Bio following the acquisition [2][3] Financial Implications - Proceeds from the sale of Pocono Pharma will be used by Nutriband Inc. to further develop its AVERSA Fentanyl product, which is projected to achieve annual U.S. sales between $80 million and $200 million [4] Product Development - Nutriband's AVERSA™ technology is designed to prevent the abuse, misuse, and accidental exposure of transdermal drugs, particularly opioids, and is protected by a broad intellectual property portfolio with patents granted in multiple countries [5][6]

Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].

Core Viewpoint - SciSparc Ltd. is progressing with its proposed merger with AutoMax Motors Ltd., which will enhance its portfolio in the electric vehicle sector while maintaining its focus on cannabinoid pharmaceuticals [1][2]. Group 1: Merger Details - SciSparc and AutoMax entered into a merger agreement in April 2024, where SciSparc will acquire 100% of AutoMax's share capital through a reverse merger [2]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [2]. - Special meetings for shareholder votes on the merger are scheduled for August 25, 2025, for SciSparc and August 28, 2025, for AutoMax [2]. Group 2: Regulatory Approvals - The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form F-4 regarding the merger on July 21, 2025 [3]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].

Group 1 - Marvel Biosciences Corp. has closed a non-brokered private placement, issuing 8,150,000 units at a price of $0.125 per unit, resulting in gross proceeds of $1,018,750 [1][2] - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of one common share at an exercise price of $0.175 per share for two years [2] - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which may also be effective in treating other neurological diseases such as autism, depression, and Alzheimer's Disease [3] Group 2 - The company is actively investigating the potential of MB-204 in addressing neurodevelopmental disorders like Rett Syndrome and Fragile X Syndrome to expand its therapeutic applications [3]

Financial Data and Key Metrics Changes - The net asset value (NAV) decreased by $223 million from the third quarter of 2024, primarily due to the decline in CVR Energy and an agreement to sell certain properties in the real estate segment [7][10]. - The investment funds were down approximately 1.6% for the quarter, with the largest decliner being the investment in Caesars [11]. - The company ended the quarter with $1.4 billion in cash and cash equivalents at the holding company and an additional $915 million at the funds [12]. Business Line Data and Key Metrics Changes - Energy segment EBITDA for Q4 2024 was $99 million, down from $204 million in Q4 2023, driven by reduced throughput and lower crack spreads [17]. - The refining margin per throughput barrel decreased to $8.37 from $15.01 in the prior year quarter due to lower crack spreads and unfavorable market derivative valuations [18]. - The automotive segment continues to lag due to previous self-inflicted wounds, but a new CEO has been appointed to implement strategies for remediation [20]. - Real estate adjusted EBITDA decreased by $5 million compared to the prior year quarter, driven by reduced sales of single-family homes [22]. - Food Packaging's adjusted EBITDA decreased by $6 million due to a shift in product mix and lower pricing [23]. - Home fashions adjusted EBITDA increased by $2 million due to lower material costs and improved manufacturing efficiencies [24]. Market Data and Key Metrics Changes - The average realized gate prices for urea were $229 per ton, while ammonia increased by 3% to $475 per ton compared to the prior year quarter [18]. Company Strategy and Development Direction - The company remains focused on building asset value and maintaining liquidity to capitalize on opportunities within and outside existing operating segments [25]. - The management emphasizes an activism strategy, leveraging the Icahn brand name and history to drive shareholder value [46][47]. Management's Comments on Operating Environment and Future Outlook - Management noted that recent improvements in crack spreads could bode well for CVR Energy, and a change in administration may resolve outstanding litigation regarding small refinery exemptions [9]. - The company anticipates that challenges in the automotive segment will be resolved and results normalized by the second half of 2025 [20]. Other Important Information - The board maintained the quarterly distribution at $0.50 per depository unit [13]. - The funds ended the quarter approximately 22% net long, adjusting for refining hedges, the fund was 35% net long [16]. Q&A Session Summary Question: Inquiry about hedge funds' net long position - The net long position was 22%, with a 35% net long excluding energy hedges. The previous position at the end of the third quarter was net short 2% [28][30]. Question: Clarification on real estate segment's indicative net asset value adjustment - The significant increase in indicative net asset value was due to an agreement to sell certain properties that exceeded book value, leading to a revaluation of remaining assets [35][37].

As filed with the U.S. Securities and Exchange Commission on February 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Blue Water Acquisition Corp. III (Exact name of registrant as specified in its charter) Cayman Islands 6770 33-2301550 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Joseph Hernandez 15 E. Putnam Avenue ...

As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. 333-274511 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SWK HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 6159 77-0435679 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. 333-274511 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SWK HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 6159 77-0435679 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...